Evidence map›Paper›PMID 35797023›Full record

ArticleJAMA otolaryngology-- head & neck surgery2022

Safety of High-Dose Nasal Theophylline Irrigation in the Treatment of Postviral Olfactory Dysfunction: A Dose-Escalation Study.

Jake J Lee, Shruti Gupta, Dorina Kallogjeri, Jay F Piccirillo

2 registry-linked trialsOpen access · bronzeAbstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in JAMA otolaryngology-- head & neck surgery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04789499 phase2completednot on this map

Smell in Covid-19 and Efficacy of Nasal Theophylline

TypeinterventionalSponsorWashington University School of MedicineRan2021 to 2021Enrolled51ConditionsCovid19, Anosmia, Olfactory Disorder, Covid-19 PandemicArmsTheophylline Powder, Placebo Comparator
NCT05947643 phase2completednot on this map

Smell in COVID-19 and Efficacy of Nasal Theophylline 3

TypeinterventionalSponsorWashington University School of MedicineRan2022 to 2025Enrolled77ConditionsCOVID-19Armstheophylline, Placebo
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Treatment of COVID-19 olfactory dysfunction with olfactory training, palmitoylethanolamide with luteolin, or combined therapy: a blinded controlled multicenter randomized trial.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2023
    Trial
  2. Trial
  3. Clinical studies in COVID-related olfactory disorders: Review of an institutional experience.World journal of otorhinolaryngology - head and neck surgery · 2024
    Article
  4. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Jake J LeeClinical Outcomes Research Office, Department of Otolaryngology-Head & Neck Surgery, Washington University School of Medicine in St Louis, St Louis, Missouri.
Shruti GuptaClinical Outcomes Research Office, Department of Otolaryngology-Head & Neck Surgery, Washington University School of Medicine in St Louis, St Louis, Missouri.
Dorina KallogjeriClinical Outcomes Research Office, Department of Otolaryngology-Head & Neck Surgery, Washington University School of Medicine in St Louis, St Louis, Missouri.
Jay F PiccirilloClinical Outcomes Research Office, Department of Otolaryngology-Head & Neck Surgery, Washington University School of Medicine in St Louis, St Louis, Missouri.
Washington University in St. Louis · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Olfaction DisordersTheophyllineHumansNasal LavageSmellTheophylline

Identifiers

PMID35797023
PMCPMC9264213
OpenAlexW4284697045

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.